432 related articles for article (PubMed ID: 23963259)
1. Current issues in dengue vaccination.
Thomas SJ; Endy TP
Curr Opin Infect Dis; 2013 Oct; 26(5):429-34. PubMed ID: 23963259
[TBL] [Abstract][Full Text] [Related]
2. Dengue human infection model performance parameters.
Endy TP
J Infect Dis; 2014 Jun; 209 Suppl 2(Suppl 2):S56-60. PubMed ID: 24872397
[TBL] [Abstract][Full Text] [Related]
3. Critical issues in dengue vaccine development.
Thomas SJ; Endy TP
Curr Opin Infect Dis; 2011 Oct; 24(5):442-50. PubMed ID: 21799408
[TBL] [Abstract][Full Text] [Related]
4. Challenges for the formulation of a universal vaccine against dengue.
Chokephaibulkit K; Perng GC
Exp Biol Med (Maywood); 2013 May; 238(5):566-78. PubMed ID: 23856907
[TBL] [Abstract][Full Text] [Related]
5. Dengue virus vaccine development.
Yauch LE; Shresta S
Adv Virus Res; 2014; 88():315-72. PubMed ID: 24373316
[TBL] [Abstract][Full Text] [Related]
6. [Dengue fever: from disease to vaccination].
Teyssou R
Med Trop (Mars); 2009 Aug; 69(4):333-4. PubMed ID: 19725380
[TBL] [Abstract][Full Text] [Related]
7. Live attenuated vaccine: the first clinically approved dengue vaccine?
Fink K; Shi PY
Expert Rev Vaccines; 2014 Feb; 13(2):185-8. PubMed ID: 24350687
[TBL] [Abstract][Full Text] [Related]
8. Dengue vaccines for travelers.
Wilder-Smith A; Deen JL
Expert Rev Vaccines; 2008 Jul; 7(5):569-78. PubMed ID: 18564012
[TBL] [Abstract][Full Text] [Related]
9. An adenovirus type 5 (AdV5) vector encoding an envelope domain III-based tetravalent antigen elicits immune responses against all four dengue viruses in the presence of prior AdV5 immunity.
Khanam S; Pilankatta R; Khanna N; Swaminathan S
Vaccine; 2009 Oct; 27(43):6011-21. PubMed ID: 19665609
[TBL] [Abstract][Full Text] [Related]
10. Challenges in reducing dengue burden; diagnostics, control measures and vaccines.
Lam SK
Expert Rev Vaccines; 2013 Sep; 12(9):995-1010. PubMed ID: 24053394
[TBL] [Abstract][Full Text] [Related]
11. Protection against dengue virus by non-replicating and live attenuated vaccines used together in a prime boost vaccination strategy.
Simmons M; Burgess T; Lynch J; Putnak R
Virology; 2010 Jan; 396(2):280-8. PubMed ID: 19913867
[TBL] [Abstract][Full Text] [Related]
12. Identifying protective dengue vaccines: guide to mastering an empirical process.
Halstead SB
Vaccine; 2013 Sep; 31(41):4501-7. PubMed ID: 23896423
[TBL] [Abstract][Full Text] [Related]
13. Dengue vaccine: opportunities and challenges.
Hatch S; Mathew A; Rothman A
IDrugs; 2008 Jan; 11(1):42-5. PubMed ID: 18175262
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of a live attenuated tetravalent candidate dengue vaccine in naïve and previously infected cynomolgus macaques.
Koraka P; Benton S; van Amerongen G; Stittelaar KJ; Osterhaus AD
Vaccine; 2007 Jul; 25(29):5409-16. PubMed ID: 17560694
[TBL] [Abstract][Full Text] [Related]
15. Dengue vaccine: hypotheses to understand CYD-TDV-induced protection.
Guy B; Jackson N
Nat Rev Microbiol; 2016 Jan; 14(1):45-54. PubMed ID: 26639777
[TBL] [Abstract][Full Text] [Related]
16. Next generation dengue vaccines: a review of candidates in preclinical development.
Schmitz J; Roehrig J; Barrett A; Hombach J
Vaccine; 2011 Sep; 29(42):7276-84. PubMed ID: 21781998
[TBL] [Abstract][Full Text] [Related]
17. Dengue vaccines: Are they safe for travelers?
Halstead SB; Aguiar M
Travel Med Infect Dis; 2016; 14(4):378-83. PubMed ID: 27343438
[TBL] [Abstract][Full Text] [Related]
18. Dengue human infection model: re-establishing a tool for understanding dengue immunology and advancing vaccine development.
Thomas SJ
Hum Vaccin Immunother; 2013 Jul; 9(7):1587-90. PubMed ID: 23466948
[TBL] [Abstract][Full Text] [Related]
19. Vaccination models and optimal control strategies to dengue.
Rodrigues HS; Monteiro MT; Torres DF
Math Biosci; 2014 Jan; 247():1-12. PubMed ID: 24513243
[TBL] [Abstract][Full Text] [Related]
20. Dengue vaccine candidates in development.
Durbin AP; Whitehead SS
Curr Top Microbiol Immunol; 2010; 338():129-43. PubMed ID: 19802583
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
